NASDAQ:HELP Cybin Q1 2027 Earnings Results & Report $6.11 -0.67 (-9.88%) Closing price 04:00 PM EasternExtended Trading$6.16 +0.05 (+0.90%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cybin missed analyst earnings expectations in its Q1 2027 results, released August 14, 2026. The company reported EPS of -$0.91 versus the -$0.80 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateAugust 14, 2026TimeBefore Market OpensConference Call4:00 PM ET Cybin EPS ResultsActual EPS-$0.91Consensus EPS -$0.80Beat/MissMissed by -$0.11One Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersCybin Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Cybin Q1 2027 Earnings FAQ Did Cybin beat earnings estimates for Q1 2027? Cybin (NASDAQ:HELP) reported earnings of -$0.91 per share for Q1 2027, missing the consensus estimate of -$0.80. The report was announced on Friday, August 14, 2026. Cybin Earnings HeadlinesCybin (NASDAQ:HELP) Stock Crosses Below 200-Day Moving Average Following Weak EarningsNovember 18 at 1:41 AM | americanbankingnews.comHelus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive DisorderNovember 16, 2026 | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 20 at 1:00 AM | Weiss Ratings (Ad)Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business HighlightsNovember 16, 2026 | globenewswire.comHelus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026November 15, 2026 | globenewswire.comHelus Pharma Files Interim Financial Statements for September 30, 2026November 13, 2026 | tipranks.comSee More Cybin Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email. Email Address About CybinCybin (NASDAQ:HELP), which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder. These compounds remain investigational and are not approved medicines. Founded in 2019, the company has conducted clinical development activities in multiple countries. Doug Drysdale has served as its chief executive officer.View Cybin ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.